Human SOST / Sclerostin Protein, His Tag (MALS verified)

Sclerostin (SOST) is also known as Sclerosteosis, VBCH, is a secreted glycoprotein with a signal peptide for secretion and a C-terminal cysteine knot-like (CTCK) domain and belongs to the Cerberus/DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. More recently Sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signalling pathway. Wnt pathway inhibition under these circumstances is antagonistic to bone formation (meaning Sclerostin antagonizes bone formation) . It has been shown that SOST binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. Sclerostin production by osteocytes is inhibited by parathyroid hormone, mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast activity is self regulated by a negative feedback system. Mutations of Sclerostin is associated with the syndrome Sclerosteosis, and reduced sclerostin expression results in a milder form of the disorder called van Buchem disease.

This protein carries a polyhistidine tag at the N-terminus. The protein has a calculated MW of 22.3 kDa. The protein migrates as 30-34 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to different glycosylation.

● -20°C to -70°C for 12 months in lyophilized state; ● -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Immobilized Human SOST, His Tag (Cat. No. HST-H5245) at 5 μg/mL (100 μL/well) can bind Human LRP-6 (20-630), Mouse IgG2a Fc Tag (Cat. No. LR6-H5253) with a linear range of 10-78 ng/mL (QC tested).